// App-Quantinova.ai

5068 : Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Researchers

Presenter

  • Neeraj Agarwal

Principal Investigators

  • Simon Chowdhury

  • Anders Bjartell

  • Byung Ha Chung

  • Andrea Juliana Pereira de Santana Gomes

  • Robert Given

  • lvaro Jurez

  • Axel Stuart Merseburger

  • Mustafa Ozguroglu

  • Hirotsugu Uemura

  • Dingwei Ye

  • Sabine Doris Brookman-May

  • Suneel Mundle

  • Sharon Anne McCarthy

  • Florence Lefresne

  • Shiva Dibaj

  • Katherine B. Bevans

  • Kim N. Chi

Medical Centers

  • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, Guy's, King's, and St. Thomas' Hospitals, and Sarah Cannon Research Institute, London, United Kingdom

  • Skane University Hospital Malmo, Lund University, Malmo, Sweden

  • Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

  • Liga Norte Riograndense Contra o Cncer, Natal, Brazil

  • Urology of Virginia, Eastern Virginia Medical School, Norfolk, VA

  • Hospital Universitario de Jerez de la Frontera, Cadiz, Spain

  • University of Schleswig-Holstein Campus Luebeck, Luebeck, Germany

  • Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey

  • Niigata University School of Medicine, Niigata, Japan

  • Fudan University Shanghai Cancer Center, Shanghai, China

  • Ludwig Maximilians University Munich, Munich, Germany

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Research & Development, Raritan, NJ, Janssen Research & Development, Los Angeles, CA

  • Janssen Research & Development, San Diego, CA

  • Janssen Research & Development, Horsham, PA, BC Cancer and Vancouver Prostate Centre, Vancouver, BC, Canada

Locations

  • United Kingdom

  • Sweden

  • Brazil

  • Spain

  • Germany

  • Turkey

  • Japan

  • China

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02489318

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved